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Viruses and transposons are efficient tools for permanently delivering foreign DNA into vertebrate genomes but
exhibit diminished activity when cargo exceeds 8 kilobases (kb). This size restriction limits their molecular genetic and
biotechnological utility, such as numerous therapeutically relevant genes that exceed 8 kb in size. Furthermore, a
greater payload capacity vector would accommodate more sophisticated cis cargo designs to modulate the expression
and mutagenic risk of these molecular therapeutics. We show that the Tol2 transposon can efficiently integrate DNA
sequences larger than 10 kb into human cells. We characterize minimal sequences necessary for transposition
(miniTol2) in vivo in zebrafish and in vitro in human cells. Both the 8.5-kb Tol2 transposon and 5.8-kb miniTol2
engineered elements readily function to revert the deficiency of fumarylacetoacetate hydrolase in an animal model of
hereditary tyrosinemia type 1. Together, Tol2 provides a novel nonviral vector for the delivery of large genetic
payloads for gene therapy and other transgenic applications.
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Introduction
The natural medaka ﬁsh hAT gene family element Tol2 [1–
3], the engineered Tc1/mariner transposons Sleeping Beauty (SB)
[4] and Frog Prince [5], and the insect-derived natural element
PiggyBac [6] represent transposons potentially suitable as
DNA transfer tools for gene discovery and gene delivery
applications in vertebrates. During the past decade, we have
been studying the Sleeping Beauty transposable element for
molecular genetic applications in vertebrates. While excep-
tionally active in higher vertebrates [7], the SB system does
have two signiﬁcant shortcomings: relatively modest cargo-
capacity and decreased activity under high transposase
concentrations (overexpression inhibition) [8,9]. The availability
of an alternative, active transposon system devoid of these
disadvantages and adapted for use in higher vertebrates
would offer tremendous potential uses in a variety of
molecular genetic and biotechnological ﬁelds. There is also
a potential for synergism between multiple transposon
systems, both in gene discovery and in gene transfer
applications. Tol2 is widely used as a transgenesis tool in the
zebraﬁsh Danio rerio due to its high level of activity in this
organism’s germline [10,11]. However, gene transfer into
cultured human cells or live mammals using Tol2 has not been
previously reported, nor have the transposon sequence
requirements for Tol2-based transposition been previously
well characterized.
Results
While testing green ﬂuorescent protein (GFP)-marked Tol2
vectors in zebraﬁsh, we noticed an unusually high number of
GFP-positive cells in embryos injected with Tol2 transposon
and synthetic transposase mRNA derived from an updated
Tol2 transcription vector (Figure 1), suggesting that this
transposon is highly active in somatic tissues. The difference
was particularly striking (over 10-fold) when percentages of
embryos exhibiting eye ﬂuorescence were evaluated (Figure
1A, right panel, red arrows). This effect was not observed
when a Sleeping Beauty transposon with the same expression
cassette was previously used in zebraﬁsh (Figure 1 and
[12,13]). To determi n ei ft h i si n c r e a s ei no v e r a l la n d
particularly eye ﬂuorescence was a result of increased
transposition, we conducted a PCR-based assay for one of
the molecular markers of the transposition reaction—
generation of a transposon-excision footprint [14]. We found
that increased GFP ﬂuorescence in Tol2-injected embryos
versus SB-injected embryos correlated with transposon
excision. The Tol2 excision band was more robust than the
SB excision band and appeared much earlier, as soon as 2 h
after injection (Figure 1B). This may reﬂect a kinetic
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as a tetramer [4,15] and may take longer to form an active
complex than Tol2, which may function like another hAT
family member Hermes, i.e., as a dimer [16]. We also note that
the high Tol2 somatic transposition rate correlates with
germline transposition: 18 of 25 tested ﬁsh gave GFP-positive
progeny (a 72% transgenesis and expression rate), with an
average founder ﬁsh transmitting an estimated ﬁve inde-
pendent insertion events (unpublished data).
This increase in GFP ﬂuorescence together with generation
of a robust excision footprint provides a rapid Tol2 activity
assay using zebraﬁsh embryos. We used this assay to address a
signiﬁcant drawback of Tol2—minimal sequences required
for transposition had not been previously deﬁned. The
commonly used Tol2 vector [11,17] has deletions encompass-
ing part of exon-2, all of exon-3, and part of exon-4 with
intervening introns. While these deletions render the trans-
posase inactive, they leave intact a signiﬁcant fraction of the
transposase open reading frame with several splice sites, as
well as promoter and polyadenylation sequences. The
presence of these sequences hinders vector design and
compromises vector utility in its application to gene
discovery, gene transfer, and gene therapy. For gene therapy
applications in particular, they pose an increased risk of
insertional mutagenesis. We made a systematic series of
deletions of the Tol2 vector and tested them in our zebraﬁsh
somatic transposition assay (Figure 1C). Surprisingly, the ﬁrst
four deletions were all active in this assay, even though two of
them removed sequences previously thought to be required
for transposon excision [18]. A combination of 59 and 39
deletions resulted in the smallest active element containing
261 nucleotides of 59 Tol2 DNA and 202 nucleotides of Tol2 39
DNA (‘‘miniTol2’’). A further truncation of the Tol2 sequences
(‘‘Tol2 clipped’’) by PCR inactivated the element, however,
indicating that there are sequence requirements beyond the
minimal 17-base inverted terminal repeats. The miniTol2
vector was subsequently tested in human cells in vitro (Figure
2) and for gene transfer in vivo (Figure 3) and demonstrated
activity statistically indistinguishable from that of the full-
length vector in each case.
In initial experiments in mammalian cells, modest gene
transfer activity was noted for Tol2 in mouse ES cells when
very high amounts of transposase-encoding plasmid were
used [10]. Tol2 has also been shown to excise in HeLa and
NIH/3T3 cells [19]; however, Tol2 transposase-mediated gene
transfer was notably not described in latter studies using
human cells. These observations combined with high activity
of Tol2 in zebraﬁsh somatic tissues prompted us to compare
the activity of Tol2 to that of the best-studied and highly
active vertebrate transposon, SB. We found that in HeLa cells,
the activity of 5-kb Tol element was indistinguishable from
that of a 2-kb SB element (Figure 2A). We then tested the
activity of Tol2 as a function of transposase concentration in
HT1080 cells by varying the amount of transposase-encoding
plasmid. Sleeping Beauty is known to exhibit decreased activity
in presence of excess transposase, a phenomenon termed
‘‘overexpression inhibition’’ [8]. We found that the Tol2
transposon system does not exhibit overexpression inhibition
within the tested transposase concentration range, while peak
gene transfer rates of the two systems are very similar despite
the difference in transposon size (Figure 2B).
Restrictions in cargo-capacity (less than 8 kb) have been
reported for integrating viral vectors including retroviruses
and lentiviruses [20]. The SB transposon system exhibits a
similar but less absolute capacity restriction, such that 10-kb
elements are notably less mobile than 2-kb–sized SB trans-
posons [8]. The larger native size of Tol2 (5 kb) versus the
presumed size of the SB progenitor (2 kb) might explain the
surprisingly high activity that was observed for the 5-kb Tol2
element in human cells (Figure 2A). We tested a larger,
greater-than-10-kb Tol2 element and found that it mediated
gene transfer nearly as efﬁciently as the 5-kb (Figure 2C)
element. Using a smaller, 2-kb miniTol2 element, we found
Tol2 activity to be largely independent of reduced cargo load.
Tol2 thus exhibits an effective, high-capacity gene transfer
capability in human cells.
Large cargo-capacity and gene transfer efﬁciency in human
cells make Tol2 an excellent candidate for molecular
Figure 1. Functional Characterization of Tol2 Transposon Sequences Using a Somatic Transposition Assay in Zebrafish
(A) Visualization of Tol2-mediated somatic transposition in zebrafish (see somatic transposition assay in Materials and Methods). Left, Injection of
transposon DNA alone results in a highly mosaic expression pattern with fewer than 5% of the animals displaying eye expression [13,50]. Middle,
Injection of SB transposase RNA does not significantly alter this somatic gene transfer distribution [12]. Right, Injection of Tol2 transposase RNA results in
gene transfer into the larval eye with over 75% of the injected embryos displaying gene transfer in this tissue at 3 dpf (red arrows).
(B) Molecular evidence of rapid Tol2-transposase activity in injected zebrafish embryos. Time-course analysis of excision from injected plasmid DNA [14]
was conducted on animals co-injected with a mixture of GFP-marked Tol2 (pTol2/S2EF1a-GM2) and SB (pT2/S2EF1a-GM2 [13] transposons with either
Tol2 or SB RNA. Note the kinetic delay in activity maturation by the presumptive obligate tetrameric SB transposase compared to Tol2 (see text). Red
arrows indicate the resulting transposase-dependent excision product.
(C) Deletion analysis identifies minimal Tol2 sequences required for gene transfer and transposon excision in zebrafish. Zebrafish embryos were injected
with depicted deletion constructs and transposase RNA and scored for GFP fluorescence at 3 d postfertilization (eye GFP column). Twenty GFP-positive
embryos were used to prepare DNA for excision PCR (Exc. Column). Striped boxes represent Tol2 transposon sequences, with red triangles indicating
terminal inverted repeats. Structural elements present in the commonly used Tol2 vector are depicted, with exons shown as open arrows and internal
inverted repeats as solid arrows. Restriction enzyme sites are indicated above the transposon drawing.
doi:10.1371/journal.pgen.0020169.g001
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Synopsis
Mobile genetic elements (transposons) are effective vehicles for the
delivery of foreign DNA for gene therapy and gene discovery
applications. Their utility in vertebrates has been, however, limited
to relatively few known elements with high activity, including the
engineered element Sleeping Beauty (SB) and the naturally occurring
fish transposon, Tol2. The authors explore and systematically unlock
some of the potential of Tol2, characterizing a minimal set of
transposon sequences required for gene transfer by the Tol2-
encoding enzyme, transposase. The authors further demonstrate full
activity of this ‘‘mini’’ element in human tissue culture cells and in
the treatment of a mouse model of tyrosinemia. Tol2 demonstrates
high cargo-capacity, readily transferring large (at least 10,000 base
pairs) DNA sequences, an ability that opens the door to an array of
molecular genetic approaches in vertebrates previously difficult or
impossible using prior tools.PLoS Genetics | www.plosgenetics.org November 2006 | Volume 2 | Issue 11 | e169 1717
Large Cargo-Capacity Vertebrate TransposonFigure 2. Large Cargo-Capacity, Tol2-mediated Transposition in Human Cells
(A) Comparison of Tol2 and SB transposons in G418-resistant colony-forming assay in HeLa cells. SB (pT2/SVneo) and Tol2 (pTol2/SVneo) transposons
with corresponding transposase-coding plasmids (pCMV-SB10 or pCMV-Tol2) were transfected into HeLa cells under conditions optimized for SB [8].
Transposon plasmid amounts were adjusted to be in equal molar ratio to 500 ng of pT2/SVNeo and the transposase construct amounts were based on
500 ng of pCMV-SB10. For negative control, a CMV-driven GFP plasmid (pGL-1) was used instead of transposase. Three independent preparations of
each transposon plasmid were used in each experiment.
(B) Tol2-mediated gene transfer activity is a positive function of Tol2 transposase activity. SB (pT2/SVneo [8]) and Tol2 (pTol2/SVneo depicted below the
graph) transposons were transfected into HT1080 cells at various ratios of transposon to transposase (pCMV-SB10 [8] and pCMV-Tol2, respectively). For
control experiments, pCMV-GFP plasmid was used. Total number of G418-resistant colonies per plate is plotted on the y-axis with error bars
representing standard error of the mean of three transfection plates. In the transposon depiction below the graph, Tol2 sequences are shown as striped
boxes with terminal inverted repeats indicated by red triangles.
(C) Tol2 gene transfer efficiencies as a function of cargo-capacity. x-axis, transposon size in kilobases; y-axis, relative efficiency. Tol2 transposons of
different sizes (2.1 kb, miniTol2/SVneo; 5.0 kb, Tol2/SVneo; 10.2 kb, Tol2/SVneo,FAHIL; two of them depicted below the graph) were transfected into
HT1080 cells and selected for G418 resistance. The number of colonies obtained using each transposon was determined, and relative efficiency was
calculated as percentage activity compared to miniTol2/SVneo 6 standard error (n ¼ 3). Red line represents a linear interpolation of activity as a
function of Tol2 transposon size.
(D) Tol2 transposon constructs. Top, pTol2/FAHIL,SVneo. ECMV-IE is CMV immediate-early enhancer (open box), PbG is the chicken beta globin
promoter (open box), pAbG is rabbit beta globin polyA, and IRES is encephalomyocarditis virus internal ribosome entry site (open box). Middle,
pminiTol2/SVneo. Bottom depiction, miniTol2 vector with multiple cloning site (MCS) designed to facilitate use of this vector by the genetics
community.
doi:10.1371/journal.pgen.0020169.g002
PLoS Genetics | www.plosgenetics.org November 2006 | Volume 2 | Issue 11 | e169 1718
Large Cargo-Capacity Vertebrate Transposonmedicine applications. We therefore tested whether Tol2 can
be used for gene delivery in live animals. We ﬁrst generated a
Tol2 transposon encoding a ﬁreﬂy luciferase expression
cassette to facilitate in vivo imaging of live animals. We then
injected 5 lg of pTol2/luc with varying amounts of pCMV-
Tol2 to achieve gene transfer into mouse liver using a rapid,
high-volume (hydrodynamic) injection method [21,22]. Luci-
ferase expression was assayed by bioluminescence imaging at
day 1 and subsequently followed through 28 wk. While we did
not observe overexpression inhibition by using large amounts
Figure 3. Tol2-Mediated, Long-term Expression and Gene Correction of Murine Model of Tyrosinemia Type 1
(A) Schematic diagram of Tol2 transposons used for injections of FAH-deficient mice. The full-length (pTol2/FAHIL) and minimal (pminiTol2/FAHIL)
versions of the transposon provide expression of both FAH and luciferase as products of a single message; pCMV-GFP served as a co-delivered control
plasmid while pCMV-Tol2 provided a source of transposase protein. PmCAGGS [51], minimal chimeric CMV enhancer/chicken beta-actin fusion
promoter; pAbG, rabbit beta-globin poly(A); ff-LUC, firefly luciferase; FAH, mouse fumarylacetoactate hydrolase cDNA; IRES, encephalomyocarditis virus
internal ribosome entry site. Then 10 mg of pTol2/FAHIL or pminiTol2/FAHIL transposon DNA plus pCMV-GFP or -Tol2 (10 mg each) was administered
by rapid, high-volume tail vein injection into sedated FAH-deficient mice (n ¼ 3 to 5 per group).
(B) The mean percentage body weight for animals in each treatment group, to determine the progression of liver disease. An asterisk (*) indicates the
time when NTBC was readministered in drinking water to prevent mortality of mice that did not receive Tol2 transposase.
(C) In vivo luciferase activity levels, assayed at indicated time points by whole body imaging and recorded as photons emitted per second as described
in Materials and Methods. The time courses of changes in body weight or in vivo luciferase enzyme activity are shown for groups of animals co-infused
with pTol2/FAHIL and GFP (squares) or Tol2 transposase (circles), or with pminiTol2/FAHIL plus GFP (triangles) or Tol2 transposase (plus sign). The mean
percentage luciferase activity at any given time point is relative to that observed at 24 h for pminiTol2/FAHIL, which demonstrated the highest transient
level of luciferase activity. The 8-wk measurement of no-transposase control animals is shaded because they required administration of NTBC for
survival at 7 wk.
(D) Images of mice infused with pminiTol2/FAHIL plus pCMV-Tol2 at indicated times (in days; upper left box), showing tissue regeneration as seen by
increasing intensity of luciferase enzyme activity detected at a location corresponding to the liver. In vivo luciferase activity levels are reported at the
bottom of each image (lower left box) as photons emitted per second (310
6).
doi:10.1371/journal.pgen.0020169.g003
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Large Cargo-Capacity Vertebrate Transposonof pCMV-Tol2 (transposon:transposase plasmid ratios of up
to 1:10), the minimal amount of transposase plasmid required
to achieve optimal, long-term expression was with trans-
poson:transposase plasmids at a ratio of 1:1 (unpublished
data).
We next investigated the ability of Tol2 to correct a mouse
model of hereditary tyrosinemia type 1 (HT1). HT1 is caused
by deﬁciency of fumarylacetoacetate hydrolase (FAH) leading
to the accumulation of fumarylacetoacetate, which is toxic to
hepatocytes. HT1 patients can be treated with 2-(2-nitro-4-
triﬂuoro-methylbenzoyl)-1,3 cyclohexanedione (NTBC), a
compound that blocks an enzyme upstream of FAH, thus
preventing toxicity [23]. Mice deﬁcient in FAH develop
symptoms of HT1, providing a model to study the disease
[24]. To test the effectiveness of Tol2 in this gene therapy
application, FAH knockout mice maintained on NTBC were
treated by hydrodynamic injection of either standard or
minimal (mini) versions of pTol2/FAHIL, a transposon that
encodes both murine FAH and ﬁreﬂy luciferase as products
of a single transcription unit (Figure 3) (A. Wilber, K. J.
Wangnesteen, Y. Chen, L. Zhuo, J. L. Frandsen, J. B. Bell, Z. J.
Chen, S. C. Ekker, R. S. McIvor, and X. Wang, unpublished
data). One day after injection, luciferase expression was
assayed by in vivo bioluminescence imaging to provide a
relative assessment of gene transfer efﬁciency for each animal
(Figure 3D). NTBC was then withdrawn to induce tyrosine-
mia. For subsequent images taken during the ﬁrst 4 wk, all
animals were administered NTBC for the 24 h preceding the
time of imaging to minimize any adverse effect resulting from
administration of the anesthetic, which is metabolized by the
liver. Previous studies have found body weight after with-
drawal of NTBC is a good measure of therapeutic effect ([25];
A. Wilber, K. J. Wangnesteen, Y. Chen, L. Zhuo, J. L. Frandsen,
J. B. Bell, Z. J. Chen, S. C. Ekker, R. S. McIvor, and X. Wang,
unpublished data). Therefore, body weight measurements
were taken for each animal to assess therapeutic efﬁcacy,
expressed as the percentage of weight at the beginning of the
experiment (Figure 3C). Animals infused with either version
of pTol2/FAHIL plus pCMV-GFP required readministration
of NTBC in the drinking water for 5 d (starting at the time
indicated by an asterisk in Figure 3B) to survive. Importantly,
animals coinjected with Tol2 transposase-encoding plasmid
Table 1. Tol2 Insertion Sites Cloned from Human HT1080 Cells and Mouse Liver pTol2/SVneo Colonies, HT1080 Cells
Site Sequence Chromosome Refseq
1 TACCTGTAATCCCAGCAC-59-Tol2-39-CCCAGCACTTTGGGAGGC 9q33.2 Intron of MNAB gene
2 TTTCCACTAATGTACAAC-59-Tol2-39-TGTACAACACAAGGACTA 1p22.3 Intergenic
3 CTAAGCACTCTTTATGAC-59-Tol2-39-TTTATGACCCTGTGGGCA 7q21.11 Intergenic
4 AGGGAACACTTAGGAACA-59-Tol2-39-TAGGAACATAATATCCAT 17p13.3 Intron of VPS53
5 TGAGAAATGAGATTTGGT-59-Tol2-39-GATTTGGTATACTGCAAG 5q33.1 Intergenic
6 GTATGTCCCTCCTTTGAT-59-Tol2-39-CCTTTGATGCAATCATCA 2p25.1 Exon of KIDINS220
7 CTAAAGGTGCCCACCACC-59-Tol2-39-CCACCACCACACCCTGCT Yq11.23 Intergenic
8 GGGAGACTGACTAGGGGT-59-Tol2-39-CTAGGGGTTGCATGGAAA 19p13.3 Intron of SIRT6
9 GCAACCTCTTCTCCCAGG-59-Tol2-39-CTCCCAGGTTCAAGTGAT 20q11.22 Intron of ITCH
10 AAAGAAAACAGTTATAAC-59-Tol2-39-GTTATAACAATATACTAC 20q11.22 Intron of ITCH
11 TGGCTCTCGGTCCTGGAG-59-Tol2-39-TCCTGGAGTCTGACGTGA 1q24.3 Intergenic
12 AATTATACATGCAGTGGG-59-Tol2-39-GCAGTGGGGGGGGAAAGC 11p15.4 Intron of RRM1
13 TTCTCTGCCTCCAATTAA-59-Tol2-39-CCAATTAAGTATTTATTA 11q24.2 Intergenic
14 TAATCCATACCAAATATG-59-Tol2-39-CAAATATAAAGGCAGATC 12q23.3 Intergenic
15 CCTTCAATCAGTATCAGA-59-Tol2-39-GTATCAGATACCCTTGGA 16p21.1 Intergenic
16 AAGAGTCACCAGATCCA -59-Tol2-39- AGATCCAGGCTGTCCCC 3p26.1 Intergenic
17 TACAAAGAGACTTAGACT-59-Tol2-39-CTTAGACTCCCACACATT 3q26.1 Intron of FLJ23049
18 GGCTCAATATATAAATT -59-Tol2-39- ATAAATTTAGACAGTGG 5q34 Intergenic
19 TGGCATTACAGGCATGAG-59-Tol2-39-GGCATGAGCCATCGCGGC 824.23 Intron of COL22A1
20 ATCCTGCACAAATATATT-59-Tol2-39-AATATATTGGCCCCACTT 20p11.21 Intergenic
21 TCAATATGGCTGCTATCA-59-Tol2-39-TGCTATCAATATCTCTTT 3q22.1 Intergenic
22 TCCTAACTGGGTTATCTG-59-Tol2-39-GTTATCTGTTAGCTGTGT 2p23.2 Intron of ALK
23 GTGTGAATGTGTACTGGG-59-Tol2-39-GTACTGGGCCATTCTCTT 2p11.2 Intergenic
24 AGGATTGTGAGCTGCTGT-59-Tol2-39-GCTGCTGTGTGCTAATAT 12p11.22 Intergenic
25 GCCCAAGGGCCCAAGGAC-59-Tol2-39-CCAAGGACCCCAGGCTGG 17q21.31 Intergenic
26 CAGAACGAGTGTTTCAAA-59-Tol2-39-GTTTCAAACCTGCTCTAT No match Repetitive
27 AGTTTCAGAGGATCCAAT-59-Tol2-39-GATCCAATGCCTTCTGAC 17qC Intergenic
28 TGCCTTGTTTGGCCTGCT-59-Tol2-39-GGCCTGCTTGCTGCTAGG 9qC Intron of Dapk2
29 GCTAAGGCCTTAAACCCT-59-Tol2-39-TAAACCCTCTAGAGTCAG 2qH3 Intron of Zfp218
30 CCCACCATTTGGTTTTAT-59-Tol2-39-GGTTTTATGAATAATATT 9qC Intron of Car12
31 CCAGGCGTCCTTTAGAGG-59-Tol2-39-TTTAGAGGTAGGTACCCC 15qE1 Intergenic
32 GGCTCTATCCCTCCTGGG-59-Tol2-39-CTCCTGGGATGGGGAGCA 11qD Exon of Ppp1r9b
33 TGGGCAATCGGTTAGTGA-59-Tol2-39-GTTAGTGAGAAATACTGG 5qE3 Intron of Fras1
34 ACACAGAAGTCAGGCATG-59-Tol2-39-CAGGCATGGCACATATGC 11qA1 Intron of Emid1
35 ACCCATGCCACCCTCACC-59-Tol2-39-CCCTCACCTGGATGCCTG 12qA3 Intron of Wdr5, Vav2
36 CCTGCATCCCAACATGCC-59-Tol2-39-AACATGCCCCAGCTTCAG 8qB3.3 Intron of Hsh2d
Integration sites 1 through 24 are from G418-resistant HT1080 colonies; sites 25 and 26 are from HT1080 transient transfection with pTol2/SVneo; and sites 27 through 36 are from mouse
liver corrected using pTol2/FAHIL.
Bold font represents target sequence duplicated after transposon integration.
doi:10.1371/journal.pgen.0020169.t001
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Large Cargo-Capacity Vertebrate Transposondid not require additional NTBC, except just prior to
anesthesia for imaging, and maintained weight during the
subsequent period of study, indicating that the metabolic
deﬁciency in these animals had been corrected [25,26].
Because the pTol2/FAHIL and pminiTol2/FAHIL trans-
posons include the luciferase-coding sequence on the same
transcript as the FAH-coding sequence, we were able to
evaluate the extent of liver repopulation resulting from
random recombination compared to co-delivery of trans-
posase in individual animals over time by bioluminescence
imaging (Figure 3C). Emitted light was measured after
luciferin injection as an indication of stable gene expression
at several times over 2 mo. Figure 3C represents luciferase
expression over time after injection of pTol2/FAHIL and
pminiTol2/FAHIL with or without pCMV-Tol2. Figure 3D
depicts the images obtained for a representative animal co-
infused with pminiTol2/FAHIL plus pCMV-Tol2, showing the
increase in luciferase activity observed during the course of
repopulation. We observed a notable decrease in transient
gene expression (day 1) for pTol2/FAHIL compared to
pminiTol2/FAHIL, possibly resulting from lower rates of
uptake of the larger pTol2/FAHIL plasmids compared to
pminiTol2/FAHIL, which are 3.1 kb smaller. Thus, the
reduction in gene transfer rate does not necessarily reﬂect
a lower transposition rate of pTol2/FAHIL. Alternatively,
sequences found within the Tol2 transposon but not within
miniTol2 may reduce transient expression of luciferase from
nonintegrated plasmid DNA. After 2 mo, FAH-deﬁcient
animals infused with pCMV-Tol2 exhibited about a 100-fold
increase in luciferase expression over animals that did not
receive pCMV-Tol2 (Figure 3D). In general, the kinetics of
liver repopulation using either the longer version or mini
derivative of the Tol2 transposon were similar, suggesting that
Tol2 is capable of efﬁciently integrating transposons as large
as 8.5 kb in vivo.
To conﬁrm that the observed stable gene expression was
due to transposition and not increased random integration,
we used inverse PCR to recover Tol2 insertions from mouse
and human chromosomes. A total of 36 integration sites were
analyzed: 24 from HT1080 cell colonies, two from HT1080
transient transfections, and ten from mouse liver (Table 1).
All had hallmarks suggesting transposition; 22 of the
integration sites displayed the expected 8-bp target-site
duplication, while the remaining two had 7-bp target-site
duplications. These results conﬁrm that Tol2 mediates
authentic transposition in mammalian cells and tissues. We
thus conclude that miniTol2 is an effective, large cargo-
capacity transposase-mediated gene transfer tool suitable for
gene therapy and other vertebrate gene transfer applications.
Discussion
We have demonstrated that the Tol2 transposable element
from medaka ﬁsh shows high potential as a mammalian gene
transfer agent. Tol2 is highly active in human cells in vitro and
in mouse liver in vivo, displaying activity comparable to that
of the most active vertebrate transposon, Sleeping Beauty. The
gene transfer rate of Tol2 in vivo is sufﬁcient to achieve
correction of the mouse model of hereditary tyrosinemia type
1. Tol2 exhibits two additional features that make it a very
attractive gene transfer system: apparent absence of over-
expression inhibition and the ability to ferry large DNA
cargo. We demonstrate that a 10-kb Tol2 transposon is nearly
as active as a 2-kb element. We deﬁned a minimized set of
inverted terminal repeat sequences required for Tol2 trans-
position and generated a high-utility miniTol2 vector for gene
transfer that can be used from zebraﬁsh to clinical applica-
tions.
The ability to efﬁciently move cargo as large as 10-kb sets
Tol2 apart from most other integrating gene transfer vectors.
The best-studied vertebrate transposon system, Sleeping
Beauty, retains only about 20% activity with such large cargo
[8]. Integrating viruses, on the other hand, can only pack
about 8 kb of exogenous DNA into their capsids, structurally
limiting cargo-capacity [20]. Bacteriophage-derived inte-
grases are capable of integrating such large cargo into
vertebrate genomes [27,28]. Integrases tend to integrate into
several pseudosites in a vertebrate genome, which can be
either an advantage or a drawback depending on application.
It appears that these preferred sites are not only different
between species but also differ depending on the cell type
used [29–32]. Recent studies demonstrate that phiC31
integrase induces chromosomal translocations in mammalian
cells, which is highly undesirable for any application [32,33].
The frequency of such events needs to be thoroughly
investigated to determine if this poses a signiﬁcant safety
risk in gene therapy applications.
One feature of Sleeping Beauty transposon system that makes
it especially attractive in a wide variety of applications
ranging from gene discovery to gene therapy is its near
random integration capabilities. SB displays little preference
for speciﬁc sequence ﬂanking the target TA dinucleotide or
for genomic region, such as genes versus intergenic regions
[34–36]. From analysis of the current and limited Tol2
integration site data, Tol2 seems to be equally unbiased
(Table 1 and [17]). A much larger sample similar to the ones
analyzed for SB [34–36] will be required to know if Tol2
exhibits any notable insertion-site preferences.
The ability to move large cargo opens new possibilities for
applications in gene therapy, gene discovery, and trans-
genesis. For gene therapy, increased cargo-capacity accom-
modates large therapeutically relevant genes such as DNA-
PKcs for X-linked severe combined immune deﬁciency [37] or
factor VIII for hemophilia A [38]. This also allows for more
complex vector design, including tissue-speciﬁc promoters,
insulators, suicide genes, and other features that may improve
both efﬁcacy and safety of such vectors. In addition, lack of
overexpression inhibition demonstrated by Tol2 will be
advantageous in designing cis vectors for co-delivery,of
transposon and transposase, something that has required a
great deal of optimization for SB. High cargo-capacity will
facilitate adaptation of Tol2 for gene discovery applications
by allowing implementation of vectors that consist of multi-
ple functional cassettes, for example, a 59 gene-trap and a 39
gene-trap, with different reporters. Tol2 has been successfully
adapted for enhancer identiﬁcation in zebraﬁsh [39], and the
newly documented ability of Tol2 to carry large cargos will
facilitate such scanning of genomic sequences for regulatory
elements. Animal biotechnology, an emerging area of trans-
genic research, will beneﬁt from a large cargo-capacity vector
that lacks overexpression inhibition.
SB and Tol2 belong to different families of transposable
elements: SB to the Tc1/mariner family and Tol2 to the hAT
family. These two highly active and very different transposon
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of research. Different transgenes can be delivered to the same
cell at the same or different time points without a concern of
cross-mobilization. One such example is generation of trans-
posase-expressing animals for cancer gene discovery. So far,
transposase-expressing mice were generated either using
plasmid transgenesis or by knock-in approaches [40–42]. It
will now be possible to easily generate lines of animals that
express SB transposase using Tol2 transposons and vice versa.
Since the original publication of Sleeping Beauty transposon
system [4], considerable research has been devoted to
characterizing and improving transposition, and multiple
laboratories have identiﬁed and published hyperactive
variants of SB transposase [8,43–45]. Without any modiﬁca-
tions, Tol2 is already much more active than SB in zebraﬁsh,
but the activity of the two systems is comparable in
mammalian cells. It remains to be determined if the Tol2
hyperactivity potential seen in zebraﬁsh can be mimicked in
mammalian cells. Other members of the same hAT family to
which Tol2 belongs display additional beneﬁcial character-
istics that strongly suggest host factors are not necessary for
transposition. Maize Ac is active in yeast [46] and Drosophila
Hermes is active in vitro [16]. These observations suggest that
Tol2 can be further developed quite rapidly and thereby
contribute insight into mechanisms of transposition as well as
serve as a tool for many other biological applications.
Materials and Methods
Transposase RNA and DNA expression vectors. The Tol2 open
reading frame was ampliﬁed by PCR using primers Tol2-F3 (59-
GCTGGATCCACCATGGAGGAAGTATGTGATTC-39) and Tol2-R1
(59-CAGACTAGTCTACTCAAAGTTGTAAAACC-39) and the pBlue-
script-based Tol2 transposase vector described by Parinov et al.
(2004) as template. The PCR fragment was ﬁrst cloned into pCRIItopo
vector (Invitrogen, Carlsbad, California, United States), resulting in
pDB595. For RNA expression, the Tol2 ORF was subcloned from
pDB595 as BamHI-SpeI fragment into BglII-SpeI digested tran-
scription vector pT3TS [47], resulting in pT3TS-Tol2 (pDB600).
pDB600 was cleaved with XbaI and transcribed with T3 polymerase
using Ambion mMessage Machine kit (Austin, Texas, United States) to
produce Tol2 mRNA. To make pCMV-Tol2, the transposase ORF was
ampliﬁed from pDB595 using Tol2-NotI-F (59-ATATGCGGCCGC-
CACCATGGAGGAAGTATG-39) and M13R primers, cloned into
pCR4topo vector (Invitrogen), and then a Tol2 NotI fragment was
excised and cloned into the NotI site of pCMV-bgal vector (Clontech,
Palo Alto, California, United States) in the forward orientation. The
SB10 ORF [4] was PCR subcloned into pT3TS to generate pT3TS-
SB10.
Tol2 transposon vectors. To construct pTol2/S2EF1a-GM2
(pDB591), the S2EF1a-GM2 expression cassette [13] was cloned as
an SphI-NruI fragment of pDB371 between EcoRV sites of pGEM-T/
Tol2 [11] in reverse orientation. To generate pTol2/SVneo (pDB625),
the G418 resistance cassette of pT2/SVneo [8] was subcloned as
HindIII fragment into EcoRV-digested pGemT-Tol2. To generate
pminiTol2/SVneo (pDB678), the same fragment was cloned between
HindIII and SwaI sites of pGEM-T/Tol2. The same fragment was
cloned into the Eco105I site of pDB633 (see below) to make pTol2/
FAHIL-SVneo (pDB691).
To deﬁne minimal sequences required for Tol2 transposition in
zebraﬁsh somatic tissues, two strategies were used. Tol2 sequences
between SwaI and XcmI sites of pDB591 were deleted to make
pDB665 (delta exon1), and sequences between XcmI and EcoO109I
sites were deleted to make pDB664 (delta repeats). Also, S2EF1a-GM2
cassette was cloned into pGEM-T/Tol2 in reverse orientation between
the following restriction enzyme sites: SwaI and EcoRV (pDB668,
delta exon 1 and repeats), EcoRV and HindIII (pDB667, delta exon 4),
and SwaI and HindIII (pDB674, Tol2mini). To make a ‘‘clipped’’
version of Tol2 transposon, S2EF1a-GM2 expression cassette was
ampliﬁed from pDB371 [13] using primers Tol2-sph-F (59-CA-
GAGGTGTAAAGTACTTGAGTAATTTTACTTGATTACTGTACT-
TAAGTATGCATGCAAGCTAGTACAAGACG-39)a n dT o l 2 - n r u - R
(59-CAGAGGTGTAAAAAGTACTCAAAAATTTTACTCAAGT-
GAAAGTACAAGTACTTATCGCGATGATAATCAGCCATACC-39).
The PCR fragment was cloned into pCR4topo vector (Invitrogen) and
sequenced.
To express FAH and ﬁreﬂy luciferase in mouse, bicistronic
expression cassette consiting of miniCAGGS promoter, mouse FAH
cDNA, encephalomyocarditis virus internal ribosome entry site,
ﬁreﬂy luciferase, and rabbit b-globin polyadenylation sequences was
subcloned as an NheI-PmeI fragment from pKT2/FAHIL (A. Wilber,
K. J. Wangnesteen, Y. Chen, L. Zhuo, J. L. Frandsen, J. B. Bell, Z. J.
Chen, S. C. Ekker, R. S. McIvor, and X. Wang, unpublished data) into
EcoRV-digested pGEM-T/Tol2 [11] (pTol2/FAHIL) or SwaI-HindIII
digested pGEM-T/Tol2 (pminiTol2/FAHIL).
In vitro transposition assays. A colony-forming assay was con-
ducted as described [8]. Brieﬂy, 3310
5 HT1080 cells were plated onto
6-cm plates and 24 h later were transfected with 1 to 2 lg of DNA
using FuGene 6 reagent (Roche, Basel, Switzerland). Two days later,
the cells were trypsinized and 3 3 10
4 cells were plated onto 10-cm
plates with complete medium supplemented with 600 lg/ml
Geneticin (G418; Invitrogen). After 10 d of selection, the cells were
stained with methylene blue and counted. Three plates of cells were
transfected for each data point using different transposon DNA
preps. For Tol2/SB activity comparison (Figure 2B), colonies were
visually counted. For comparison of different-size Tol2 elements
(Figure 2C), colonies were counted using ImageJ software (http://rsb.
info.nih.gov/ij). The number of colonies obtained in transfection
including transposase was divided by the number of colonies
obtained in control transfection to compute gene transfer efﬁciency.
The efﬁciency of miniTol2/SVneo was set as 100%.
Molecular analysis of genomic integration sites. DNA was isolated
from cultured cells or mouse liver using the Puregene DNA
puriﬁcation system (Gentra Systems, Minneapolis, Minnesota, United
States). DNA was digested and used in an adapted inverse PCR (iPCR)
protocol [12]. Tol2-speciﬁc iPCR primers were Tol2-R3 (59-ACTGGG-
CATCAGCGCAATTCAATTG-39)a n dT o l 2 - F 7( 5 9-AGCAGGA-
TAAAACCTTGTATGCATT-39) for the ﬁrst round and Tol2-R4 (59-
ATAATACTTAAGTACAGTAATCAAG-39)a n dT o l 2 - F 8( 5 9-
CTCAAGTAAGATTCTAGCCAGATAC-39) for the nested reaction.
For iPCR of cell clones, Neo-resistant colonies were picked and
ampliﬁed 2 wk after tranfection with pDB625 and pCMV-Tol2.
Genomic DNA was extracted, digested with NheI, SpeI, and XbaI and
ligated in a dilute reaction. The ﬁrst round of iPCR was performed
with Tol2-R3 and Tol2-F7, and a second with Tol2-R4 and Tol2-F7.
The PCR products were isolated by gel electrophoresis, and
sequenced using primers Tol2-R4 or Tol2-F7. For cloning of miniTol2
insertion sites, HT1080 cells were transfected with miniTol2SVneo
and pCMV-Tol2 and grown for 4 d without selection. Genomic DNA
was extracted and digested with AﬂIII (which cuts the vector twice
outside of the transposon and leaves incompatible ends) SpeI and
XbaI, ligated in a dilute reaction, and one round of PCR was
performed with Tol2-R3 and Tol2-F8. The resultant products were
used in a Topo-cloning reaction (Invitrogen), and two insertions were
identiﬁed by sequencing using M13-F and M13-R primers. For the
mouse insertion sites, genomic DNA was extracted from each of ﬁve
liver lobes of one FAH-deﬁcient mouse 2 mo after injection with
pTol2-FAHIL. The DNA was digested with NheI, BamHI, XhoI, and
BsiWI, which do not cut vector sequences, blunted with Klenow
fragment, and ligated in a dilute reaction. Two rounds of iPCR were
performed and sequenced as described above for cell clones.
Zebraﬁsh somatic transposition assays. For SB/Tol2 comparison in
the GFP ﬂuorescence analysis (Figure 1), one-cell stage zebraﬁsh
embryos were injected with a mixture of 20 pg of pT2/S2EF1a/GM2
(pDB371) and pTol2/S2EF1a/GM2 (pDB591) each. Some of the
embryos were then injected with 25 pg of T3TS-Tol2 or 25 pg of
T3TS-SB RNA. Dead and grossly abnormal embryos were removed,
and GFP ﬂuorescence was scored at 3 d postfertilization. Randomly
chosen embryos were photographed using Zeiss Axioscope II with
Zeiss Axiocam using Zeiss Axiovision software. For excision analysis,
embryos were injected with either a mixture of 20 pg of pT2/S2EF1a/
GM2 (pDB371) DNA, 20 pg of pTol2/S2EF1a/GM2 (pDB591) DNA, and
25 pg of T3TS-Tol2 RNA or a mixture of 20 pg of pT2/S2EF1a/GM2
(pDB371) DNA, 20 pg of pTol2/S2EF1a/GM2 (pDB591) DNA, and 25
pg of T3TS-SB10 RNA. Twenty embryos were pooled at each
indicated time point, and the DNA was prepared using a modiﬁed
genomic DNA preparation protocol [48] and used for excision PCR
[14]. To compare different Tol2 truncations, embryos were ﬁrst
injected with 25 pg of appropriate plasmid solution, and then all
plasmid-injected embryos were injected with 25 pg of T3TS-Tol2
RNA using the same needle. Surviving and grossly normal embryos
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GFP-positive embryos were used for DNA preparation. DNA was
dissolved in 50 ll of TE and diluted 1:1 in water; 1 ll of this solution
was subsequently used for excision PCR (see above).
Animals and plasmid injections. Normal C57BL/6 mice and
FAHDexon 5 transgenic (tg) mice [24], 18 to 25 g, were bred in a
speciﬁc pathogen-free environment at the University of Minnesota.
FAH-deﬁcient mice were maintained on drinking water supple-
mented with NTBC at a concentration of 7.5 mg/ml. Plasmids were
delivered primarily to the liver using a rapid, high-volume tail vein
injection procedure [21,22] as previously described [49]. Only animals
that received a complete injection in less than 8 s were used for
subsequent studies.
In vivo bioluminescent imaging. At various times after injection of
DNA, animals were anesthetized by intraperitoneal injection of 160
mg/kg ketamine plus 0.8 mg/kg acepromazine and 0.08 mg/kg
butorphanol. One hundred milliliters of 28.5 mg/ml luciferin
substrate was then injected intraperitoneally. At 4 to 5 min after
injection of substrate, the live anesthetized mice were imaged for 1 s
to 2 min using an intensiﬁed, charge-coupled device camera (Series
100; Xenogen, Hopkinton, Massachusetts, United States) as described
[49]. Raw values of luciferase activity were recorded as photons of
light emitted per second.
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